1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

FINANCE ROUNDUP: Global Blood Doubles Post-IPO, GlobeImmune Considers Options, VC Deals Surge

 
• By Mandy Jackson

Global Blood Therapeutics launched an initial public offering at $20 per share and its stock price more than doubled to $43.11 at the end of its first day of trading on Aug. 12, proving that investors may be concerned about a biotechnology bubble, but they're not overly worried that it will burst soon.

Global Blood Therapeutics launched an initial public offering at $20 per share and its stock price more than doubled to $43.11 at the end of its first day of trading on Aug. 12, proving that investors may be concerned about a biotechnology bubble, but they're not overly worried that it will burst soon.

Then again, while the South San Francisco-based sickle cell drug developer grossed $120m from the sale of 6m shares, it was the only biotech to complete an IPO in the US during the week of Aug. 10 to 14. And GlobeImmune, a company that struggled to price its first-ever offering in 2014, admitted that it's considering a sale or other strategic alternatives

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Therapy Areas

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.